Dr. Nathalie Jacque | Consultant Hematologist Dubai
CMC Hospital – DHCC 2
English French



Dr Nathalie Jacque is a Consultant Hematologist in CMC Dubai. She received her French Board of Hematology in 2011 after 6 years of residency in Paris.

After her graduation, she began a research program at Cochin Institute working on treatment of acute leukemia. She obtained her PhD in Hematology and Oncology from Paris Sorbonne University in 2015.

At the same time, she was a consultant hematologist in Pitié Salpêtrière Hospital in Paris. She was first in charge of an intensive care unit (chemotherapy for acute leukemia, autologous and allogeneic stem cell transplantation) and then of the daily care hospital (treatments of lymphomas, myelomas, myelodysplastic syndromes, acute leukemias; post allogeneic SCT consultations; Immunoglobuline and blood transfusions; iron therapy).

She is a member of the Lymphoma study association (LYSA), Francophone Myeloma Intergroup (IFM), French society of bone marrow transplant and cellular therapy (SFGM-TC).



  • Diagnosis and treatment of all hematological disorders either benign or malignant: anemia, cytopenias, immunodeficiency, myeloid and lymphoid cancers.
  • Chemotherapy and oral therapy, iron and immunoglobuline perfusions and blood transfusion.
  • Bone marrow biopsy and aspirations, lumbar puncture



  • Ecole Doctorale Hématologie Oncogenèse Biothérapies Paris Sorbonne University, PHD 2015
  • Doctor of Medecine (MD), Paris VI University, Hematology Specialty. 2011
  • Master of Science, Paris V, « Cellular biology, physiology, pathology, 2010
  • Medical Residency, Paris, 2005-2011



  • Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation. Forgeard N, Baron M, Caron J, Boccon-Gibod C, Krzisch D, Guedes N, Morel V, Jacque N, Ouzegdouh M, Choquet S, Bravetti C, Nguyen-Khac F, Chapiro E, Leblond V, Roos-Weil D. Haematologica. 2022
  • CAR-T cell therapy in primary central nervous system lymphoma (PCNSL): the clinical experience of the French LOC network. Alcantara M, Houillier C, Blonski M, Rubio MT, Willems L, Waultier Rascalou A, Le Garff-Tavernier M, Maloum K, Bravetti CM, Souchet L, Roos-Weil D, Morel V, Uzunov M, Metz C, Dhib-Charfi M, Nguyen S, Shor N, Psimaras D, Weiss N, Jacque N, Solorzano S, Gauthier N, Le Cann M, Norol F, Soussain C, Choquet S. Blood. 2021
  • How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Garnache-Ottou F, Vidal C, Biichlé S, …, Jacques N …, Deconinck E. Blood Adv. 2019
  • Chronic lymphocytic leukemia Jacque N, Leblond V. Presse Med. 2019
  • RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia. Hospital MA, Jacquel A, Mazed F, Saland E, Larrue C, Mondesir J, Birsen R, Green AS, Lambert M, Sujobert P, Gautier EF, Salnot V, Le Gall M, Decroocq J, Poulain L, Jacque N, Fontenay M, Kosmider O, Récher C, Auberger P, Mayeux P, Bouscary D, Sarry JE, Tamburini J. Leukemia. 2018
  • Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J. Sci Adv. 2015
  • Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Thiago TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D. Blood. 2015
  • Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia. Sujobert P, Poulain L, Paubelle E, Zylbersztejn F, Grenier A, Lambert M, Townsend EC, Brusq JM, Nicodeme E, Decroocq J, Nepstad I, Green AS, Mondesir J, Hospital MA, Jacque N, Christodoulou A, Desouza TA, Hermine O, Foretz M, Viollet B, Lacombe C, Mayeux P, Weinstock DM, Moura IC, Bouscary D, Tamburini J. Cell Rep. 2015
  • Targeting glutamine uptake in AML. Jacque N, Bouscary D. Oncoscience. 2014
  • Chimerism analysis in peripheral blood using indel quantitative real-time PCR is a useful tool to predict post-transplant relapse in acute leukemia. Jacque N, Nguyen S, Golmard JL, Uzunov M, Garnier A, Leblond V, Vernant JP, Bories D, Dhédin N. Bone Marrow Transplant. 2015
  • The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J. Leukemia. 2012
  • The eukaryotic initiating factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia. Green AS, Grabar S, Tulliez M, Park S, Al-Nawakil C, Chapuis N, Jacque N, Willems L, Azar N, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D, Tamburini J. Br J Haematol. 2012

Popular Treatments Offered

تقديم العلاجات الشائعة


Dr Nathalie Jacque is a Consultant Hematologist in Dubai, UAE who is fluent in French.

Insurance coverage can vary depending on your insurance provider and policy. Visit Our Website Insurance page for more Details.

It's advisable to bring any relevant medical records, test results, or medications you are currently taking to your appointment. It's also helpful to prepare a list of questions you have about your condition or treatment options.

Related services

الخدمات ذات الصلة

Start chat
Chat with us
I’d like to book an appointment